Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: A CIBMTR analysis

H. J. Khoury, M. Kukreja, J. M. Goldman, T. Wang, J. Halter, M. Arora, V. Gupta, D. A. Rizzieri, B. George, A. Keating, R. P. Gale, D. I. Marks, P. L. McCarthy, A. Woolfrey, J. Szer, S. A. Giralt, R. T. Maziarz, J. Cortes, M. M. Horowitz, S. J. Lee

Research output: Contribution to journalArticle

Abstract

Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in advanced phases of CML, which may permit early allografting for responding patients. To identify prognostic factors in allograft recipients previously treated with IM, we analyzed 449 allogeneic hematopoietic SCTs performed from 1999 to 2004 in advanced-phase CML, using the data reported to the Center for International Blood and Marrow Transplant Research. CML patients in second chronic phase (CP2, n=184), AP (n=185) and BP (n=80) received HLA-identical sibling (27%), related (3%), or matched or mismatched unrelated donor (70%), peripheral blood (47%) or BM (53%) hematopoietic SCT after myeloablative (78%) or non-myeloablative (22%) conditioning. In all, 52% in CP2, 49% in AP and 46% in BP received IM before hematopoietic SCT. Disease-free survival was 35-40% for CP2, 26-27% for AP and 8-11% for BP. Cumulative incidence of acute and chronic GVHD and TRM were not affected by the stages of CML or pre-hematopoietic SCT IM exposure. Multivariate analyses showed that conventional prognostic indicators remain the strongest determinants of transplant outcomes. In conclusion, there are no new prognostic indicators of the outcomes of allogeneic hematopoietic SCT for advanced-phase CML in the IM era.

Original languageEnglish (US)
Pages (from-to)810-816
Number of pages7
JournalBone marrow transplantation
Volume47
Issue number6
DOIs
StatePublished - Jun 1 2012
Externally publishedYes

Fingerprint

Homologous Transplantation
Blast Crisis
Transplants
Unrelated Donors
Disease-Free Survival
Allografts
Siblings
Multivariate Analysis
Bone Marrow
Imatinib Mesylate
Incidence
Research

Keywords

  • accelerated phase
  • allogeneic transplantation
  • blast phase
  • CML
  • imatinib
  • outcomes

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Khoury, H. J., Kukreja, M., Goldman, J. M., Wang, T., Halter, J., Arora, M., ... Lee, S. J. (2012). Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: A CIBMTR analysis. Bone marrow transplantation, 47(6), 810-816. https://doi.org/10.1038/bmt.2011.194

Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era : A CIBMTR analysis. / Khoury, H. J.; Kukreja, M.; Goldman, J. M.; Wang, T.; Halter, J.; Arora, M.; Gupta, V.; Rizzieri, D. A.; George, B.; Keating, A.; Gale, R. P.; Marks, D. I.; McCarthy, P. L.; Woolfrey, A.; Szer, J.; Giralt, S. A.; Maziarz, R. T.; Cortes, J.; Horowitz, M. M.; Lee, S. J.

In: Bone marrow transplantation, Vol. 47, No. 6, 01.06.2012, p. 810-816.

Research output: Contribution to journalArticle

Khoury, HJ, Kukreja, M, Goldman, JM, Wang, T, Halter, J, Arora, M, Gupta, V, Rizzieri, DA, George, B, Keating, A, Gale, RP, Marks, DI, McCarthy, PL, Woolfrey, A, Szer, J, Giralt, SA, Maziarz, RT, Cortes, J, Horowitz, MM & Lee, SJ 2012, 'Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: A CIBMTR analysis', Bone marrow transplantation, vol. 47, no. 6, pp. 810-816. https://doi.org/10.1038/bmt.2011.194
Khoury, H. J. ; Kukreja, M. ; Goldman, J. M. ; Wang, T. ; Halter, J. ; Arora, M. ; Gupta, V. ; Rizzieri, D. A. ; George, B. ; Keating, A. ; Gale, R. P. ; Marks, D. I. ; McCarthy, P. L. ; Woolfrey, A. ; Szer, J. ; Giralt, S. A. ; Maziarz, R. T. ; Cortes, J. ; Horowitz, M. M. ; Lee, S. J. / Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era : A CIBMTR analysis. In: Bone marrow transplantation. 2012 ; Vol. 47, No. 6. pp. 810-816.
@article{f78cbfb45f554e8b96c15cba24b88370,
title = "Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: A CIBMTR analysis",
abstract = "Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in advanced phases of CML, which may permit early allografting for responding patients. To identify prognostic factors in allograft recipients previously treated with IM, we analyzed 449 allogeneic hematopoietic SCTs performed from 1999 to 2004 in advanced-phase CML, using the data reported to the Center for International Blood and Marrow Transplant Research. CML patients in second chronic phase (CP2, n=184), AP (n=185) and BP (n=80) received HLA-identical sibling (27{\%}), related (3{\%}), or matched or mismatched unrelated donor (70{\%}), peripheral blood (47{\%}) or BM (53{\%}) hematopoietic SCT after myeloablative (78{\%}) or non-myeloablative (22{\%}) conditioning. In all, 52{\%} in CP2, 49{\%} in AP and 46{\%} in BP received IM before hematopoietic SCT. Disease-free survival was 35-40{\%} for CP2, 26-27{\%} for AP and 8-11{\%} for BP. Cumulative incidence of acute and chronic GVHD and TRM were not affected by the stages of CML or pre-hematopoietic SCT IM exposure. Multivariate analyses showed that conventional prognostic indicators remain the strongest determinants of transplant outcomes. In conclusion, there are no new prognostic indicators of the outcomes of allogeneic hematopoietic SCT for advanced-phase CML in the IM era.",
keywords = "accelerated phase, allogeneic transplantation, blast phase, CML, imatinib, outcomes",
author = "Khoury, {H. J.} and M. Kukreja and Goldman, {J. M.} and T. Wang and J. Halter and M. Arora and V. Gupta and Rizzieri, {D. A.} and B. George and A. Keating and Gale, {R. P.} and Marks, {D. I.} and McCarthy, {P. L.} and A. Woolfrey and J. Szer and Giralt, {S. A.} and Maziarz, {R. T.} and J. Cortes and Horowitz, {M. M.} and Lee, {S. J.}",
year = "2012",
month = "6",
day = "1",
doi = "10.1038/bmt.2011.194",
language = "English (US)",
volume = "47",
pages = "810--816",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era

T2 - A CIBMTR analysis

AU - Khoury, H. J.

AU - Kukreja, M.

AU - Goldman, J. M.

AU - Wang, T.

AU - Halter, J.

AU - Arora, M.

AU - Gupta, V.

AU - Rizzieri, D. A.

AU - George, B.

AU - Keating, A.

AU - Gale, R. P.

AU - Marks, D. I.

AU - McCarthy, P. L.

AU - Woolfrey, A.

AU - Szer, J.

AU - Giralt, S. A.

AU - Maziarz, R. T.

AU - Cortes, J.

AU - Horowitz, M. M.

AU - Lee, S. J.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in advanced phases of CML, which may permit early allografting for responding patients. To identify prognostic factors in allograft recipients previously treated with IM, we analyzed 449 allogeneic hematopoietic SCTs performed from 1999 to 2004 in advanced-phase CML, using the data reported to the Center for International Blood and Marrow Transplant Research. CML patients in second chronic phase (CP2, n=184), AP (n=185) and BP (n=80) received HLA-identical sibling (27%), related (3%), or matched or mismatched unrelated donor (70%), peripheral blood (47%) or BM (53%) hematopoietic SCT after myeloablative (78%) or non-myeloablative (22%) conditioning. In all, 52% in CP2, 49% in AP and 46% in BP received IM before hematopoietic SCT. Disease-free survival was 35-40% for CP2, 26-27% for AP and 8-11% for BP. Cumulative incidence of acute and chronic GVHD and TRM were not affected by the stages of CML or pre-hematopoietic SCT IM exposure. Multivariate analyses showed that conventional prognostic indicators remain the strongest determinants of transplant outcomes. In conclusion, there are no new prognostic indicators of the outcomes of allogeneic hematopoietic SCT for advanced-phase CML in the IM era.

AB - Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in advanced phases of CML, which may permit early allografting for responding patients. To identify prognostic factors in allograft recipients previously treated with IM, we analyzed 449 allogeneic hematopoietic SCTs performed from 1999 to 2004 in advanced-phase CML, using the data reported to the Center for International Blood and Marrow Transplant Research. CML patients in second chronic phase (CP2, n=184), AP (n=185) and BP (n=80) received HLA-identical sibling (27%), related (3%), or matched or mismatched unrelated donor (70%), peripheral blood (47%) or BM (53%) hematopoietic SCT after myeloablative (78%) or non-myeloablative (22%) conditioning. In all, 52% in CP2, 49% in AP and 46% in BP received IM before hematopoietic SCT. Disease-free survival was 35-40% for CP2, 26-27% for AP and 8-11% for BP. Cumulative incidence of acute and chronic GVHD and TRM were not affected by the stages of CML or pre-hematopoietic SCT IM exposure. Multivariate analyses showed that conventional prognostic indicators remain the strongest determinants of transplant outcomes. In conclusion, there are no new prognostic indicators of the outcomes of allogeneic hematopoietic SCT for advanced-phase CML in the IM era.

KW - accelerated phase

KW - allogeneic transplantation

KW - blast phase

KW - CML

KW - imatinib

KW - outcomes

UR - http://www.scopus.com/inward/record.url?scp=84862205894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862205894&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.194

DO - 10.1038/bmt.2011.194

M3 - Article

C2 - 21986636

AN - SCOPUS:84862205894

VL - 47

SP - 810

EP - 816

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -